Cr | IStock | Getty pictures
A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.
Another potential competitor for blockbuster fat -lane treatments of Eli Lilly And Novo Nordisk Only positive data shown – but this time it comes from China.
In a study in the late stage in China, an experimental weekly injection developed by the Chinese pharmaceutical manufacturer Hengrui Pharma and his partner Kaailera therapeutics based in the USA brought the drug manufacturers onto the route to take consent there.
Kailera belongs to several companies such as Merck, Novo Nordisk and Regeneron, who have won the Chinese market in search of a medication that could win a piece of the booming market for weight loss medicines. In May 2024, Kaailera licensed the rights outside of the Greater China region for several experimental medication from Hengrui in return for more than $ 100 million in advance payments and short-term payments, a share share of 20% and almost $ 6 billion in future milestones.
As the medication, which was designated in the study with the HRS9531, was carried out in the study: After 48 weeks, it helped the patient to lose almost 18% of their body weight, which is more than 16% higher than those on a placebo saw.
Almost 9 out of 10 people who received the injection lost at least 5% of their body weight, and 44.4% of the patients achieved at least 20% weight loss, according to companies. After 48 weeks there was no plateau.
The companies did not open any specific safety data or how well the patients tolerated the medication, and only said that these results match previous data for treatment and other GLP-1. Most undesirable events from the injection were gastrointestinal -related and light to moderate heaviness, the companies said.
Hengrui will submit an application for admission for the medication in China. In the meantime, Kailera will start global studies that use higher doses and keep patients in treatment for longer, said Ron Renaud, CEO of the startup, in the publication.
It will probably still take a few years before HRS9531 comes into the market, especially in the USA and other nations outside China. However, the results of the drug seem to be promising and, as a potential competitor to position Eli Lilly's weekly weight loss, zepbound.
Both drugs work by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1 and glucose-dependent insulinotropic polypeptide or gip. The combination is intended to slow down the emptying of the stomach, feel people full longer and suppress appetite by slowing down hunger signals in the brain.
In two phase, three studies that enroll about 3,000 adults with obesity or type -2 -diabetes, Zepbound helped the patient to lose an average of up to 21% of their body weight for over 72 weeks.
It is difficult to compare the results of various clinical studies directly, especially since the latest results on HRS9531 only came from more than 500 patients. However, the drug still reached significant weight loss for over 48 weeks and increased the hopes of its potential over a longer period of time.
In the meantime, the weekly injection of Novo Nordisk only aims at GLP-1.
Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.
Latest in the healthcare system Tech: 23Andme co-founder Wojcicki's non-profit organization acquires genetic test company
Anne Wojcicki, co -founder and Chief Executive Officer from 23Andme Inc., during the South by Southwest (SXSW) Festival in Austin, Texas, USA, on Friday, March 10, 2023.
Jordan Vonderhaar | Bloomberg | Getty pictures
Well, guys, after a long saga, Anne Wojcicki has officially regained control of the competitive gene tests 23Andme.
Wojcicki was a co -founder of 23Andme and served as CEO until the company applied for insolvency protection in Chapter 11 in March. Your new non -profit TTAM Research Institute has completed the acquisition of the business preparations for personal genome service and research services from 23Andme, the company said on Monday.
“As part of TTAM, 23Andme continues to work and offers customers personalized DNA test and research services,” said the company in a press release. “TTAM is committed to supplying customers from elections and transparency with their data, including the opportunity to change their decision on whether they should take part in research.”
According to Wall Street Journal, TTAM is an abbreviation for the first letters from 23Andme.
23Andme shot with DNA test kits at home in the mainstream, which gave the customer an insight into their family history and genetic profiles. However, the five-time CNBC Disruptor 50-company had trouble getting recurring income and lifelong research and therapeutic agencies increased to the public.
When it became clear that 23andmes finance data was shaky, Wojcicki submitted several suggestions to take the company privately while she was still his managing director. These plans were unsuccessful and ultimately had to compete against other potential buyers in an insolvency auction.
And of course there were some unexpected twists.
In May, Regeneron announced Pharmaceuticals to acquire most assets of 23 and 23Ande for 256 million US dollars after it is ahead during insolvency auction. But Wojcicki submitted a separate offer of 305 million US dollars via TTAM and urged to reopen the auction.
A month later she did exactly that and TTAM announced that it successfully overrunned Regeneron.
“I am thrilled that the TTAM research institute can continue the 23Andme mission to help people access, understand and benefit from human genome,” said Wojcicki in June.
Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.
Comments are closed.